Search Menu
Photonics Media Photonics Buyers' Guide Photonics Spectra BioPhotonics EuroPhotonics Vision Spectra Photonics Showcase Photonics ProdSpec Photonics Handbook
More News

Bioptigen Inc.

Facebook Twitter LinkedIn Email Comments
Technology company Bioptigen Inc. of Durham, N.C., has received clearance from Health Canada to begin marketing its handheld ophthalmic imaging systems for patient use. The Envisu series spectral domain ophthalmic imaging system uses low-power near-infrared light to produce high-resolution depth-resolved images of eye structures in real time. Based on OCT technology, the systems are expected to enable greater understanding of eye disease progression, detection and treatment. “Now that Bioptigen has regulatory approval to market our technology in Canada and the European Union, adults and children can begin benefiting from this flexible and detailed imaging platform that complements existing diagnostic techniques and treatments,” said Eric Buckland, president and CEO.

Apr 2012
AmericasBiophotonicsBioptigenBusinessCanadaEnvisu SDOISEnvisu Spectral Domain Optimal Imaging SystemEric BucklandEuropeEuropean UnionHealth Canadaimagingmedical devices and eye diseaseNorth Carolinaopthalmic imaging systemoptical coherence tomographRapidScanSDOCTspectral domain OCTSpectral domain optical coherence tomographyvisualization of the eye

back to top
Facebook Twitter Instagram LinkedIn YouTube RSS
©2020 Photonics Media, 100 West St., Pittsfield, MA, 01201 USA,

Photonics Media, Laurin Publishing
x Subscribe to BioPhotonics magazine - FREE!
We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.